UPClytics
View all cases

UPC APP 43786/2024

Jul 26, 2024·EP3167888 Unitary patent · TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Case details
Status
Case Closed
Action
Generic
Category
Costs assessments
Parties
Claimants
Representatives
Respondents
Representatives
Division
Hamburg LD
Technology
  • Chemistry
    Biotechnology · Pharmaceuticals
Language
English
First decided
Aug 1, 2025
EPO Opposition
How this compares
How long the court takes to reach a first decision.
Median days to first decision
All UPC124
Hamburg LDLocked
Judge Sabine KlepschLocked
Judge Alima ZanaLocked
Judge Stefan SchillingLocked
Judge Rudi GoedeweeckLocked

At the UPC: Samsung Group (57 cases)·AstraZeneca Group (13 cases)

This dispute contains 6 other proceedings

UPC CoA 744/2025·UPC CFI 674/2025·UPC CFI 51/2025·UPC CFI 40/2025·UPC CoA 402/2024 and 1 more

3 other defendants litigating the same or a related patent

UPC CFI 642/2024·UPC CoA 405/2024·UPC CFI 124/2024

Start a free trial to see how each one ended.

More cases: Hamburg LD·2024

Decisions
  • 2025-08-01

    Summary: Hamburg Local Division (1 August 2025) issued a costs decision following the dismissal of Alexion Pharmaceuticals' provisional measures application against Samsung Bioepis. The court assessed Samsung Bioepis' recoverable litigation costs, disallowing the costs of two UK solicitors as disproportionate but allowing the costs of the private expert Prof. Kontermann and reasonable travel expenses.

    Show the legal issues (4)
    • Cost decision (R. 151 RoP)
    • Reasonable and proportionate legal costs
    • Expert costs
    • UK solicitor costs disallowed
Document titleDatePublic
Case closed2026-05-07Not public
Receipt2026-01-06Not public
Cover sheet2026-01-06Not public
Other document Defendant2026-01-06Not public
Communication2025-12-03Not public
Headnote-and-Keywords2025-08-01Not public
Outcome of the Order2025-08-01Not public
Order with grounds2025-08-01Public
Order with grounds2025-08-01Not public
Receipt2025-07-23Not public